Conditions include chronic granulomatous disease and leukocyte adhesion deficiency syndrome ... and then delivered to the patient via an IV or subcutaneous injection weekly, biweekly, or monthly.

Patients in the EU with Fanconi anaemia ... from the FDA on Kresladi (marnetegragene autotemcel) for severe leukocyte adhesion deficiency-I (LAD-I), its lead product, which is due by 30th June ...

The company’s solutions include ex vivo lentiviral vector treatments for Fanconi anemia, leukocyte adhesion deficiency-I ... Rocket also finished enrolling patients in its Phase 1 trial for ...

making it a promising target for treating AML patients. Several CD123 x CD3 TCEs are being developed to direct T cells to CD123-expressing tumor cells (62). Through a CRISPR screen, deficiency in FUT8 ...

As the countdown to the launch of its first therapeutic continues, Rocket Pharmaceuticals is fueling up its commercial team. The biotech on Monday appointed Sarbani Chaudhuri as its new chief ...

We recently published a list of 10 Stocks Under $10 that Will Triple.In this article, we are going to take a look at where Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT) stands against other stocks ...